A catheter hub that cracks after sterilisation, a diagnostic housing that attracts contamination, an implantable polymer part with unstable surface energy – these are rarely material problems alone. In practice, the question is often which coating suits medical plastics when the substrate already meets the design brief, but the surface does not.
For technical decision-makers, that question cannot be answered by naming a single “best” coating. Medical plastics vary widely in chemistry, thermal stability, geometry, regulatory constraints and intended patient contact. The right answer sits at the intersection of substrate behaviour, functional target, process window and validation effort.
Which coating suits medical plastics depends on the application
Medical plastics are selected because they are lightweight, design-flexible and often cost-efficient in volume production. Yet their surface properties are frequently the limiting factor. A polymer may offer the necessary mechanical performance while still falling short in terms of barrier effect, lubricity, adhesion behaviour, chemical resistance or biocompatibility.
That is why coating selection should begin with the failure mode or target function rather than with the coating family itself. If the component must reduce friction in a minimally invasive device, the priorities differ from those of an electronics enclosure that needs dielectric protection. If a part faces repeated sterilisation cycles, the decisive factor may be long-term stability rather than initial performance.
In regulated medical environments, surface technology also has to be judged by what it does not do. A coating that changes dimensions, introduces extractables, bridges fine tolerances or degrades under gamma or EtO sterilisation can create more risk than value. The coating process must therefore be considered as part of the product system, not as a cosmetic add-on.
The key criteria before choosing a coating
Before discussing technologies, it helps to structure the decision around a few technical questions. The first is substrate compatibility. Plastics such as PEEK, PEI, PC, ABS, PA, PP or medical-grade silicone respond very differently to vacuum, temperature, plasma activation and thin-film deposition. A process that performs well on a high-temperature engineering polymer may be unsuitable for a more sensitive thermoplastic.
The second is functional priority. In medical plastics, coatings are usually selected to improve one or more of the following: barrier performance, chemical resistance, friction behaviour, cleanability, electrical insulation, adhesion promotion or biointerface properties. In many projects, these targets compete. A very dense barrier layer may not be the best option if flexibility is critical.
The third is geometry. Complex three-dimensional components, internal surfaces, sharp edges and microfeatures can strongly influence coating uniformity. Some technologies are line-of-sight by nature, while others can form highly conformal layers even on intricate parts.
Finally, there is the industrial question. Can the process be validated? Is thickness reproducible batch to batch? Does the coating fit into an existing manufacturing route, or does it require a dedicated system architecture? For high-volume or regulated production, these points are not secondary.
Parylene for medical plastics: where it fits best
Parylene is often a strong candidate when medical plastics require a pinhole-free, highly conformal thin film with low added mass. Because the deposition occurs from the gas phase and forms the coating at molecular level, it is particularly suitable for complex geometries, narrow gaps and delicate structures.
For many medical plastic components, Parylene offers a valuable combination of barrier protection, dielectric performance and biocompatibility. It can help reduce moisture ingress, protect sensitive electronics, improve chemical resistance and create a defined surface without imposing high thermal loads on the substrate. That matters for polymers that would distort, embrittle or outgas under more aggressive conditions.
Its strengths are especially clear in applications such as sensor housings, diagnostic cartridges, microcomponents, implant-adjacent electronics and polymer parts that need reliable insulation. Parylene is also relevant when dimensional precision matters, because functional layers can be achieved in very small thickness ranges.
That said, Parylene is not automatically the answer to every wear or tribology problem. While it can support low-friction behaviour in some cases, highly abrasive mechanical contact may require a different or hybrid approach. Adhesion on certain low-energy plastics can also depend on carefully engineered pre-treatment. In other words, the process chain matters as much as the coating chemistry.
Plasma processes: when surface modification is enough
Not every medical plastic needs a deposited barrier layer. In some cases, plasma treatment is the more technically appropriate and economically efficient route. Plasma can activate, clean or functionalise the surface without adding a significant coating thickness.
This is especially useful where adhesion is the primary issue. Bonding, printing, overmoulding or adhesive joining on polymers often depends on surface energy and cleanliness. Plasma treatment can create a more reactive surface, improving downstream process reliability without changing the bulk properties of the component.
For medical plastics, plasma also has value in targeted surface functionalisation. Depending on the process design, it can influence wettability, interface behaviour and preparation for subsequent thin-film deposition. When used as a pre-treatment step before Parylene or other coating systems, it often determines whether the final layer performs consistently over time.
The limitation is straightforward: plasma activation alone does not replace a true barrier or wear-protection layer where such properties are required. If the application demands long-term chemical shielding or electrical insulation, surface activation by itself is unlikely to be sufficient.
PVD and hybrid coatings: useful, but only on the right polymer system
PVD-based thin films can provide excellent hardness, defined optical behaviour, conductive or decorative effects and strong wear performance. In medical technology, they may be relevant for selected polymer components where a functional metallic or ceramic-like surface is required.
However, suitability depends heavily on the plastic. Many PVD processes involve thermal and energetic loads that are well tolerated by metals, but less forgiving for polymers. The coefficient of thermal expansion, outgassing tendency and surface stability of the substrate become critical. If these factors are not controlled, the result may be poor adhesion, stress-related cracking or unstable performance during sterilisation and use.
This is where hybrid process design becomes valuable. A plasma pre-treatment, adhesion-promoting interlayer or combined thin-film architecture can make coatings feasible on plastics that would otherwise be difficult to treat. For example, a polymer part may need both improved adhesion and a defined barrier or wear function. In such cases, a tailored sequence of activation, interlayer formation and final coating often outperforms any single-step standard process.
The engineering effort is higher, but so is the level of control. For medical components with demanding specifications, that trade-off is often justified.
Which coating suits medical plastics under sterilisation and compliance demands?
Sterilisation is one of the most common reasons why promising coating concepts fail late in development. A surface that performs well under laboratory handling can lose adhesion, change friction behaviour or develop microdefects after repeated autoclave, gamma, EtO or plasma sterilisation cycles.
That is why sterilisation compatibility should be part of coating selection from the outset. The relevant question is not whether a coating survives a single cycle, but whether it maintains its functional properties within the actual product lifecycle. This includes ageing behaviour, interaction with cleaning agents and possible changes at the coating-substrate interface.
Compliance adds another layer of complexity. In medical applications, coating selection must support documentation, reproducibility and risk assessment. Process windows, surface analytics and thickness control are not merely quality features – they are part of the route to qualification. Technical teams should therefore favour coating solutions that can be characterised and scaled with clear process discipline.
A practical way to decide
If the requirement is conformal barrier protection, electrical insulation or moisture resistance on complex medical plastic geometries, Parylene is often the first technology to evaluate. If the main issue is adhesion, wettability or surface activation before a secondary process step, plasma treatment may be sufficient. If the target is wear resistance, specific optical function or a metallic thin film effect, PVD or a hybrid architecture may be appropriate, provided the polymer and process window allow it.
The decisive point is that coating choice should never be separated from component design, material selection and manufacturing strategy. A technically sound evaluation includes substrate testing, surface analysis, adhesion assessment, sterilisation trials and consideration of production scale. Standard answers rarely survive contact with real medical applications.
For companies developing sensitive polymer components, the most reliable path is usually application-specific process development rather than selecting from a catalogue of generic coatings. That is where a specialised partner with expertise in Parylene, plasma, PVD, CVD and custom system design can reduce risk early and create a route to reproducible production.
When the surface has to do more than the plastic alone can deliver, the right coating is not the one with the strongest headline claim. It is the one that meets the functional target, respects the substrate and remains stable where it counts most – in validated use.
